IU Health Central Indiana Cancer Center

Indianapolis, Indiana 46219

0 studies enrolling now · 4 studies all time

What they study most

Adenocarcinoma of the Lung, Bladder Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Cancer, Urothelial Carcinoma

Studies at this site

• Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects — Completed
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC — Stopped early
• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer — Completed
• Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor — Stopped early